LTRN - Lantern Pharma Inc. Stock Price and Quote

LTRN [NASD]

Index	-	P/E	-	EPS (ttm)	-1.32	Insider Own	23.35%	Shs Outstand	10.84M	Perf Week	2.09%
Market Cap	52.27M	Forward P/E	-	EPS next Y	-1.88	Insider Trans	-21.06%	Shs Float	8.32M	Perf Month	-14.77%
Income	-14.40M	PEG	-	EPS next Q	-0.47	Inst Own	30.60%	Short Float / Ratio	1.71% / 3.65	Perf Quarter	-19.08%
Sales	-	P/S	-	EPS this Y	-19.40%	Inst Trans	0.88%	Short Interest	0.14M	Perf Half Y	-7.47%
Book/sh	5.45	P/B	0.85	EPS next Y	-27.00%	ROA	-21.30%	Target Price	13.00	Perf Year	-33.26%
Cash/sh	5.15	P/C	0.90	EPS next 5Y	-	ROE	-22.40%	52W Range	4.05 - 7.92	Perf YTD	-23.10%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-41.35%	Beta	-
Dividend %	-	Quick Ratio	19.80	Sales past 5Y	-	Gross Margin	-	52W Low	14.69%	ATR	0.37
Employees	14	Current Ratio	19.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.82	Volatility	6.42% 7.50%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	42.30%	Profit Margin	-	Rel Volume	1.27	Prev Close	4.65
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 20 AMC	Payout	-	Avg Volume	39.03K	Price	4.64
Recom	2.00	SMA20	-8.17%	SMA50	-12.97%	SMA200	-11.53%	Volume	7,662	Change	-0.11%

Oct-07-21

Initiated

H.C. Wainwright

Buy

$32

Mar-20-23 04:01PM	Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights Business Wire
Mar-15-23 08:00AM	Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting Business Wire
Mar-13-23 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET Business Wire +9.30%
06:16AM	Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week MarketWatch
06:00AM	Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank Business Wire
08:00AM	Loading…
Mar-09-23 08:00AM	Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors Business Wire
Mar-08-23 08:00AM	Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lanterns Drug Candidates, Featuring Zoltan Szallasi, M.D. Business Wire
Mar-06-23 08:00AM	Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers Business Wire
Mar-02-23 08:00AM	Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials Business Wire
Feb-27-23 08:00AM	Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352 Business Wire
Feb-21-23 12:10PM	7 AI Penny Stocks That Could Skyrocket in 2023 InvestorPlace
Feb-15-23 08:00AM	Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates Business Wire
Feb-01-23 04:55AM	LTRN: LP-184 & LP-284 in the Spotlight Zacks Small Cap Research
Jan-17-23 08:00AM	Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184s Phase 1 Clinical Trial in Q2 2023 Business Wire
Jan-05-23 08:59AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma Business Wire -11.94%
06:15AM	Loading…
Dec-31-22 06:15AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2022 Earnings Call Transcript Insider Monkey
Dec-15-22 08:00AM	Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting Business Wire
Dec-13-22 08:00AM	Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) Business Wire
Dec-02-22 01:46PM	10 Best Artificial Intelligence Stocks Under $10 Insider Monkey
08:00AM	Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET GlobeNewswire
Nov-22-22 08:00AM	Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting Business Wire
Nov-08-22 04:48AM	LTRN: Harmonic Screening Underway Zacks Small Cap Research
Nov-07-22 04:01PM	Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights Business Wire
Nov-02-22 08:00AM	Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4 Business Wire
Oct-31-22 08:00AM	Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET Business Wire
Oct-25-22 08:00AM	Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences Business Wire
Oct-21-22 07:00AM	Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET Business Wire
Oct-20-22 07:59AM	Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300 Business Wire
Oct-13-22 10:48AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate Simply Wall St. +5.89%
Oct-11-22 04:00PM	Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET ACCESSWIRE
08:00AM	Loading…
Oct-05-22 08:00AM	Lantern Pharma to Present at Upcoming Investor Conferences Business Wire
Sep-23-22 08:50AM	Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting Business Wire
Sep-19-22 08:50AM	Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D. Business Wire
Sep-14-22 12:05PM	Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate Benzinga +5.51%
08:50AM	Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer Business Wire
Aug-30-22 09:00AM	Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwrights 24th Annual Global Investment Conference in September 2022 Business Wire -6.37%
Aug-19-22 08:30AM	Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) ACCESSWIRE -5.56%
Aug-09-22 08:20AM	LTRN: Music to Our Ears: Harmonic to Start Zacks Small Cap Research
Aug-08-22 04:01PM	Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights Business Wire
Aug-01-22 07:00AM	Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET Business Wire
Jul-14-22 07:00AM	Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer Business Wire -11.82%
May-12-22 07:00AM	Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month PR Newswire -8.06%
May-06-22 10:29AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate Simply Wall St.
May-05-22 08:00AM	LTRN: First Quarter 2022 Financial and Operational Results Zacks Small Cap Research
07:00AM	Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022 Business Wire
May-03-22 04:01PM	Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights PR Newswire +5.03%
Apr-26-22 07:15AM	Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors PR Newswire
Apr-22-22 07:00AM	Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET PR Newswire
Apr-14-22 11:10AM	Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) ACCESSWIRE
Mar-22-22 07:00AM	Lantern Pharma Announces Extension of Existing Share Repurchase Program PR Newswire
Mar-14-22 07:00AM	Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting PR Newswire -8.63%
06:38AM	LTRN: 2021 Results Zacks Small Cap Research
Mar-10-22 04:05PM	Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights PR Newswire
Mar-03-22 07:00AM	Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 PR Newswire
Feb-15-22 06:59AM	Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio PR Newswire +5.09%
Feb-02-22 05:38PM	Sanders Morris Harris Llc Buys Roth CH Acquisition V Co, The Walt Disney Co, Mastercard Inc, ... GuruFocus.com -5.66%
Jan-26-22 04:30PM	RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28 ACCESSWIRE
Jan-24-22 07:00AM	Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System PR Newswire
Jan-20-22 08:04AM	LTRN: Multiple Collaborations Illuminating Way Forward Zacks Small Cap Research
Jan-18-22 06:30AM	Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors PR Newswire -9.22%
Jan-12-22 06:03AM	Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284 PR Newswire +9.02%
Jan-04-22 09:29AM	Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference PR Newswire -6.61%
Dec-14-21 09:01AM	Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting PR Newswire
Nov-22-21 09:00AM	Lantern Pharma Announces Share Repurchase Program PR Newswire
Nov-12-21 09:40AM	Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day PR Newswire
Nov-11-21 09:15AM	Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting PR Newswire
Nov-09-21 09:00AM	Lantern Pharma to Participate in Two Upcoming Investor Conferences PR Newswire
Nov-08-21 08:44AM	We Think Lantern Pharma (NASDAQ:LTRN) Can Afford To Drive Business Growth Simply Wall St.
Nov-04-21 09:37AM	Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting PR Newswire
Nov-03-21 09:41AM	LTRN: 3Q:21 Results Zacks Small Cap Research
Nov-01-21 04:05PM	Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights PR Newswire
09:15AM	Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships PR Newswire
Oct-27-21 09:05AM	Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations PR Newswire -7.15%
08:02AM	Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development PR Newswire
Oct-25-21 04:57PM	Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET PR Newswire +5.26%
Oct-04-21 04:30PM	36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021 ACCESSWIRE -5.70%
Sep-30-21 09:00AM	Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021 ACCESSWIRE
Sep-28-21 09:20AM	Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer PR Newswire -7.71%
Sep-22-21 09:00AM	Lantern Pharma CEO to Present at the Benzinga Healthcare Small Cap Conference on September 29th PR Newswire
Sep-07-21 09:00AM	Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September PR Newswire
Sep-02-21 08:59AM	Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives PR Newswire
Aug-30-21 08:59AM	FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas PR Newswire
Aug-19-21 03:15PM	Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock Benzinga -5.39%
08:50AM	Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration PR Newswire
Aug-16-21 08:20AM	Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer PR Newswire -5.00%
Aug-11-21 08:21AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer PR Newswire
Aug-09-21 05:42AM	How Many Lantern Pharma Inc. (NASDAQ:LTRN) Shares Do Institutions Own? Simply Wall St.
Aug-05-21 06:21AM	LTRN: 2Q:21 Results Zacks Small Cap Research
Jul-29-21 04:01PM	Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights PR Newswire
Jul-27-21 08:00AM	Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S PR Newswire
Jul-22-21 04:08PM	Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET PR Newswire
Jul-20-21 08:12AM	Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models Benzinga +17.19%
07:00AM	Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 PR Newswire
Jun-13-21 10:30PM	Is Lantern Pharma Inc. (LTRN) A Good Stock To Buy Now? Insider Monkey
May-25-21 08:14AM	Lantern Pharma - Using AI to Transform The Cost & Risk of Cancer Drug Development Benzinga
May-17-21 08:55AM	10 Best AI Stocks under $50 Insider Monkey +5.56%
May-12-21 07:45AM	LTRN: 1Q:21 Results: 4.6 Billion Datapoints and Counting Zacks Small Cap Research
May-10-21 06:35AM	Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth Simply Wall St.
May-03-21 04:32PM	Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights PR Newswire +6.46%
02:45PM	Lantern Pharma Inc to Host Earnings Call ACCESSWIRE

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kreis Leslie W.	10% Owner	Nov 08	Sale	4.40	350,000	1,540,000	71,774	Nov 09 09:39 PM
Fletcher Aaron G.L.	10% Owner	Nov 08	Sale	4.40	350,000	1,540,000	71,774	Nov 09 09:37 PM
Kreis Leslie W.	10% Owner	Sep 02	Sale	5.20	6,445	33,514	20,930	Sep 07 04:54 PM
Fletcher Aaron G.L.	10% Owner	Sep 02	Sale	5.20	6,445	33,514	20,930	Sep 07 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience